REVIEW OF ETOPOSIDE SINGLE-AGENT ACTIVITY

[1] AHMANN DL, 1976, CANCER TREAT REP, V60, P633

[2] ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71

[3] BENDER RA, AM J HEMATOL

[4] BERNASCONI C, 1976, ERKRANKUNGEN MYELOPO

[5] BRUNNER K, 1979, P AM ASSOC CANC RES, V20, P308

[6] BRUNNER KW, 1976, CANCER TREAT REP, V60, P1377

[7] EPIPODOPHYLLOTOXIN VP-16213 IN ACUTE NON-LYMPHOBLASTIC LEUKEMIA [J]. BRITISH MEDICAL JOURNAL, 1975, 4 (5990) : 227 - 227

[8] RANDOMIZED PHASE-II TRIAL WITH VP-16-213(ETOPOSIDE) IN THE TREATMENT OF ADVANCED BREAST-CANCER [J]. ONKOLOGIE, 1981, 4 (02): : 80 - 83

[9] CAVALLI F, 1977, SCHWEIZ MED WSCHR, V107, P1960

[10] CAVALLI F, 1978, CANCER TREAT REP, V62, P473

[1] AHMANN DL, 1976, CANCER TREAT REP, V60, P633

[2] ARNOLD AM, 1979, CANCER CHEMOTH PHARM, V3, P71

[3] BENDER RA, AM J HEMATOL

[4] BERNASCONI C, 1976, ERKRANKUNGEN MYELOPO

[5] BRUNNER K, 1979, P AM ASSOC CANC RES, V20, P308

[6] BRUNNER KW, 1976, CANCER TREAT REP, V60, P1377

[7] EPIPODOPHYLLOTOXIN VP-16213 IN ACUTE NON-LYMPHOBLASTIC LEUKEMIA [J]. BRITISH MEDICAL JOURNAL, 1975, 4 (5990) : 227 - 227

[8] RANDOMIZED PHASE-II TRIAL WITH VP-16-213(ETOPOSIDE) IN THE TREATMENT OF ADVANCED BREAST-CANCER [J]. ONKOLOGIE, 1981, 4 (02): : 80 - 83

[9] CAVALLI F, 1977, SCHWEIZ MED WSCHR, V107, P1960

[10] CAVALLI F, 1978, CANCER TREAT REP, V62, P473